Acorda Therapeutics (ACOR) Beats Q4 EPS Expectations; Revs Heavy
Get Alerts ACOR Hot Sheet
Price: $13.50 +8.87%
EPS Growth %: -139.7%
Financial Fact:
License and royalty revenue: 2.26M
Today's EPS Names:
BFRI, HCTI, IMPM, More
EPS Growth %: -139.7%
Financial Fact:
License and royalty revenue: 2.26M
Today's EPS Names:
BFRI, HCTI, IMPM, More
Join SI Premium – FREE
Acorda Therapeutics (NASDAQ: ACOR) reported Q4 EPS of $0.45, $0.27 better than the analyst estimate of $0.18. Revenue for the quarter came in at $72.64 million versus the consensus estimate of $69.16 million.
For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.
For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FreightCar America (RAIL) Misses Q4 EPS by 6c, provides guidance
- Alpine Immune Sciences (ALPN) Reports FY Loss of $0.64
- Lantern Pharma (LTRN) Tops Q4 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!